Publication Name	World Journal of Clinical Oncology
Manuscript ID	42410
Country	Türkiye

Received	2018-09-25 03:29
Peer-Review Started	2018-09-25 08:43
To Make the First Decision	2018-11-01 06:51
Return for Revision	2018-11-08 07:57
Revised	2018-11-08 10:49
Second Decision	2019-01-03 10:49
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2019-01-06 05:11
Articles in Press	2019-01-06 05:11
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2019-02-21 09:27
Publish the Manuscript Online	2019-02-22 04:33

ISSN	2218-4333 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Minireviews
Article Title	Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy
Manuscript Source	Invited Manuscript
All Author List	Ozkan Kanat and Hulya Ertas
ORCID	Author(s) ORCID Number Ozkan Kanat http://orcid.org/0000-0001-6973-6540 Hulya Ertas http://orcid.org/0000-0001-8306-4349
Funding Agency and Grant Number
Corresponding Author	Ozkan Kanat, MD, PhD, Professor, Department of Medical Oncology, Faculty of Medicine, Uludag University, Gorukle, Bursa 16059, Türkiye. ozkanat@uludag.edu.tr
Key Words	Angiogenesis inhibition; Second-line chemotherapy; Colorectal cancer; Bevacizumab; Aflibercept; Ramucirumab
Core Tip	Anti-angiogenic treatment is an essential part of the current armamentarium against metastatic colorectal cancer (mCRC). For now, bevacizumab is the only drug licensed for the treatment of chemotherapy-naïve patients with mCRC. However, patients undergoing first-line bevacizumab-based therapy eventually develop disease progression and become candidates for second-line chemotherapy. In this manuscript, we discuss the available anti-angiogenic therapeutic strategies that have been proven to be useful in the treatment of patients with mCRC in whom first-line bevacizumab-based therapy was ineffective.
Publish Date	2019-02-22 04:33
Citation	Kanat O, Ertas H. Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy. World J Clin Oncol 2019; 10(2): 52-61
URL	https://www.wjgnet.com/2218-4333/full/v10/i2/52.htm
DOI	https://dx.doi.org/10.5306/wjco.v10.i2.52

Full Article (PDF)	WJCO-10-52.pdf
Full Article (Word)	WJCO-10-52.docx
Manuscript File	42410-Review.docx
Answering Reviewers	42410-Answering reviewers.pdf
Audio Core Tip	42410-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	42410-Conflict-of-interest statement.pdf
Copyright License Agreement	42410-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	42410-Language certificate.pdf
Peer-review Report	42410-Peer-review(s).pdf
Scientific Misconduct Check	42410-Scientific misconduct check.pdf
Scientific Editor Work List	42410-Scientific editor work list.pdf